This Article Full Text Full Text (PDF) All Versions of this Article: 34/11/2549    most recent 01.STR.0000094731.63690.FFv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hamada, J.-i. Articles by Ushio, Y. Search for Related Content PubMed PubMed Citation Articles by Hamada, J.-i. Articles by Ushio, Y. Related Collections Other Stroke Treatment - Surgical

(Stroke. 2003;34:2549.)
© 2003 American Heart Association, Inc.

Original Contributions

Effect on Cerebral Vasospasm of Coil Embolization Followed by Microcatheter Intrathecal Urokinase Infusion Into the Cisterna Magna

A Prospective Randomized Study

Jun-ichiro Hamada, MD, PhD; Yutaka Kai, MD, PhD; Motohiro Morioka, MD, PhD; Shigetoshi Yano, MD, PhD; Takamasa Mizuno, MD; Teruyuki Hirano, MD; Kiyoshi Kazekawa, MD, PhD Yukitaka Ushio, MD, PhD

From the Departments of Neurosurgery, Neurology, and Neuroradiology, Kumamoto University School of Medicine, Kumamoto (J.H., Y.K., M.M., S.Y., T.M., T.H., Y.U.), and Department of Neurosurgery, Fukuoka University, Chikushi Hospital, Fukuoka (K.K.), Japan.

Correspondence to Jun-ichiro Hamada, MD, Department of Neurosurgery, Kumamoto University School of Medicine, 1-1-1 Honjo, Kumamoto 860-856, Japan. E-mail jhamada{at}kaiju.medic.kumamoto-u.ac.jp

Background and Purpose— Vasospasm remains the leading cause of death and permanent neurological disability in patients with aneurysmal subarachnoid hemorrhage (SAH). The objective of our prospective randomized trial of coil embolization followed by intrathecal urokinase infusion into the cisterna magna (ITUKI therapy) was to test its effectiveness in preventing or alleviating the severity of ischemic neurological deficits caused by vasospasm.

Methods— We enrolled 110 patients with ruptured intracranial aneurysms eligible for coil embolization and randomly assigned them to embolization with (n=57) or without (n=53) ITUKI therapy performed within 24 hours of aneurysmal SAH. The incidence of symptomatic vasospasms and the clinical outcomes, based on the Glasgow Outcome Scale, 6 months after SAH onset were assessed.

Results— There were no side effects or adverse reactions attributable to ITUKI therapy. Symptomatic vasospasm occurred in 5 patients (8.8%) with and 16 (30.2%) without ITUKI therapy; the difference was significant (P=0.012). Although the mortality rate did not differ between the groups, patients with ITUKI therapy had significantly better outcomes than those without (P=0.036).

Conclusions— Our results demonstrate that ITUKI therapy significantly reduced the occurrence of symptomatic vasospasm. Although it did not completely prevent vasospasms, ITUKI therapy resulted in a lower rate of permanent neurological deficits.

Key Words: cerebral aneurysm • cisterna magna • embolization, therapeutic • urokinase • vasospasm

This article has been cited by other articles:

				R. L. Macdonald Advances in Vascular Surgery Stroke, February 1, 2004; 35(2): 375 - 380. [Full Text] [PDF]